Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1-2]
• Journavx (suzetrigine) is indicated for the treatment of moderate to severe acute pain in adults.
• In adults undergoing abdominoplasty or bunionectomy, suzetrigine significantly improved SPID48 scores at 48 hours post-operation compared to placebo, with a mean difference of 38.76 (95% CI: 28.97–48.54; p < 0.00001).
• The results demonstrated minimal heterogeneity across studies (I² = 5%), indicating consistency in effectiveness outcomes.
• No specific effectiveness outcomes were reported for subgroups within the study populations.
• In adults undergoing abdominoplasty or bunionectomy (n=2,768), suzetrigine reduced the risk of overall adverse events compared to placebo (RR = 0.86), with specific reductions in nausea (RR = 0.72) and dizziness (RR = 0.57).
• No significant differences were observed between suzetrigine and placebo for constipation, headache, vomiting, moderate adverse events, or serious adverse events.
• There is no population information available in the reviewed studies.